Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate.

This human clinical study describes the design and dose selection rationale for a Phase 3 randomized controlled trial of hydromethylthionine mesylate (a methylene blue derivative), an oral tau aggregation inhibitor being investigated for Alzheimer’s disease treatment. Researchers selected a 16 mg/day dose based on prior pharmacokinetic, safety, and efficacy data from earlier phase trials, with the goal of inhibiting tau protein aggregation while maintaining tolerability. The article presents the scientific basis and trial design rather than reporting primary efficacy outcomes from the Phase 3 trial itself.